China NMPA Product Recall - Electrophysiological recording system

GE Medical Systems Information Technologies, Inc. initiated a voluntary Class II recall of its CardioLab Electrophysiological Recording Systems, as reported by its agent, GE Healthcare Systems Trading Development (Shanghai) Co., Ltd., on August 6, 2018, and subsequently published by the National Medical Products Administration (NMPA) on November 6, 2018. The recall addresses a significant safety concern: the power cord system of the affected devices is prone to damage, potentially exposing live conductors. This defect poses a risk of electric shock, which could lead to severe patient injuries, including arrhythmias or cardiac arrest. The regulatory framework for this action in China is the NMPA. Despite the serious nature of the issue, the specific batches implicated in the recall were not distributed or sold within China. Therefore, the required action for the Chinese market was for GE Healthcare to formally report the incident to the NMPA, fulfilling its regulatory obligations without a need for direct product retrieval in the region. This proactive measure by GE Healthcare emphasizes its dedication to upholding high standards of product safety and quality.